Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Drugs. 2013 Feb;73(2):131-58. doi: 10.1007/s40265-013-0007-5.
Patients with viral infections of the central nervous system (CNS) may present with a variety of neurological symptoms, most commonly dominated by either encephalitis or meningitis. The aetiological panorama varies in different parts of the world as well as over time. Thus, virological first-line diagnostics must be adapted to the current epidemiological situation and to the individual patient history, including recent travels. This review focuses on the diagnostics and treatment of viral CNS infections in the immunocompetent host from a Northern European perspective. Effective vaccines are available for viruses such as poliovirus and tick-borne encephalitis virus (TBEV) and for the childhood diseases morbilli (measles), rubella (German measles), parotitis (mumps) and varicella (chickenpox). However, cases do appear due to suboptimal immunization rates. In viral CNS infections, epidemiological surveillance is essential for establishing preventive strategies and for detecting emerging viruses. Knowledge of the possibilities and limitations of diagnostic methods for specific viral CNS infections is vital. A positive cerebral spinal fluid (CSF) polymerase chain reaction (PCR) finding is usually reliable for aetiological diagnosis. The demonstration of intrathecal antibody synthesis is useful for confirming the aetiology in a later stage of disease, hitherto sufficiently evaluated in herpes simplex encephalitis (HSE) and tick-borne encephalitis (TBE). Despite improved virological and differential diagnostic methods, aetiology remains unknown in about half of the cases with suspected viral encephalitis. Antiviral treatment is available chiefly for infections caused by herpesviruses, and acyclovir (aciclovir) is the drug of choice for empirical therapy in suspected viral encephalitis. However, randomized, controlled antiviral trials have only been conducted for HSE, while such studies are lacking in other viral CNS infections. Viral cytolysis and immune-mediated mechanisms may contribute to varying extents to neurological damage. Although the brain damage is believed to depend, to a varying degree, on the intrathecal host immune response, the use of corticosteroids in viral CNS infections is scarcely studied, as is specific treatment for neuroinflammation. Improved antiviral and immunomodulating treatment is desirable. Since neurological sequelae are still abundant, follow-up after severe viral CNS disease must include a neuropsychological assessment and an individually adapted rehabilitation plan.
患有中枢神经系统 (CNS) 病毒感染的患者可能会出现多种神经症状,最常见的是脑炎或脑膜炎。病因在世界各地以及随着时间的推移而变化。因此,病毒学的一线诊断必须适应当前的流行病学情况和个体患者的病史,包括近期旅行史。本综述重点关注北欧免疫宿主中枢神经系统病毒感染的诊断和治疗。针对脊髓灰质炎病毒和蜱传脑炎病毒 (TBEV) 等病毒以及儿童疾病麻疹、风疹、腮腺炎和水痘,已有有效的疫苗。然而,由于免疫接种率不理想,仍会出现病例。在中枢神经系统病毒感染中,流行病学监测对于制定预防策略和检测新出现的病毒至关重要。了解特定中枢神经系统病毒感染的诊断方法的可能性和局限性至关重要。阳性脑脊液聚合酶链反应 (PCR) 结果通常可可靠地进行病因诊断。在疾病的后期阶段,检测到鞘内抗体合成有助于确认病因,这在单纯疱疹脑炎 (HSE) 和蜱传脑炎 (TBE) 中得到了充分评估。尽管病毒学和鉴别诊断方法有所改进,但约有一半疑似病毒性脑炎的病例病因仍未知。抗病毒治疗主要用于疱疹病毒感染,阿昔洛韦(更昔洛韦)是疑似病毒性脑炎经验性治疗的首选药物。然而,只有 HSE 进行了随机对照抗病毒试验,而其他病毒性中枢神经系统感染则缺乏此类研究。病毒细胞溶解和免疫介导的机制可能在不同程度上导致神经损伤。尽管据信脑损伤在一定程度上取决于鞘内宿主免疫反应,但皮质类固醇在病毒性中枢神经系统感染中的应用以及针对神经炎症的特异性治疗研究甚少。需要改进抗病毒和免疫调节治疗。由于仍存在大量神经后遗症,因此严重病毒性中枢神经系统疾病后的随访必须包括神经心理学评估和个体化的康复计划。